(Q37630911)

21 August 2017

1 reference

title

Proton pump inhibitor and clopidogrel interaction: fact or fiction? (English)

1 reference

21 August 2017

1 reference

2

Charles Hennekens

1 reference

21 August 2017

Loren Laine

1

1 reference

PubMed ID

19904241

21 August 2017

language of work or name

English

0 references

publication date

10 November 2009

1 reference

The American Journal of Gastroenterology

21 August 2017

1 reference

21 August 2017

105

1 reference

21 August 2017

34-41

1 reference

21 August 2017

1

1 reference

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Effect of clopidogrel added to aspirin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in coll

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers. A gastroscopic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Will measuring vasodilator-stimulated phosphoprotein phosphorylation help us optimize the loading dose of clopidogrel?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

The CYP2C19 enzyme polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Proton pump inhibitors: an update of their clinical use and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Prasugrel versus clopidogrel in patients with acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Prasugrel in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2009.638

21 January 2018

Identifiers

DOI

10.1038/AJG.2009.638

1 reference

21 August 2017

1 reference

PubMed ID

19904241